Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398094 | 0.92 | OPRM1 (0.50) | OPRM1OPRD1OPRK1SIGMAR1CCR4 | |
| SCHEMBL20749672 | 0.85 | SIGMAR1 (0.47) | OPRM1OPRD1OPRK1SIGMAR1CCR4 | |
| SCHEMBL15819328 | 0.84 | EZH2 (0.43) | THRBKMT2A | |
| SCHEMBL15819327 | 0.84 | EZH2 (0.43) | THRBKMT2A | |
| SCHEMBL19390905 | 0.83 | EZH2 (0.42) | OPRM1OPRD1OPRK1CCR4THRB | |
| SCHEMBL16402619 | 0.83 | EZH2 (0.53) | — | |
| SCHEMBL16402441 | 0.83 | EZH2 (0.51) | — | |
| SCHEMBL15839169 | 0.83 | EZH2 (0.57) | — | |
| SCHEMBL15839173 | 0.83 | EZH2 (0.56) | — | |
| SCHEMBL15839157 | 0.82 | EZH2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150764-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-12-11 | — | — | US | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| EP-3022184-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010049-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | OPRM1 4199/4885OPRD1 3960/4885OPRK1 2381/4885 |
| US-10150764-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | OPRM1 4199/4885OPRD1 3960/4885OPRK1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.